Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules that induce targeted protein degradation.
• PROTACs overcome limitations of small-molecule inhibitors (SMIs) by targeting proteins with smooth surfaces and multiple domains.
• They offer a promising approach for challenging therapeutic targets in various diseases.

Purpose of the Study:

• To provide an overview of PROTAC technology, focusing on third-generation PROTAC development.
• To review recent clinical trials of PROTACs in cancer therapy.
• To discuss novel mechanisms and signaling pathways in cancer relevant to PROTACs.

Main Methods:

• Literature review of PROTAC technology and clinical trial data.
• Analysis of novel findings in cancer mechanisms and signaling pathways.
• Discussion of strategies to enhance PROTAC efficacy and specificity.

Main Results:

• PROTACs enable targeted degradation of proteins, including those previously undruggable by SMIs.
• Recent clinical trials demonstrate the potential of PROTACs in cancer therapy.
• Novel signaling pathways and protein scaffolding functions are identified as potential therapeutic targets.

Conclusions:

• PROTAC technology represents a significant advancement in drug discovery and development.
• Targeted protein degradation offers a powerful strategy for treating cancers, especially those with complex molecular mechanisms.
• Further research into PROTAC design and application holds promise for improved cancer treatment outcomes.